Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

@inproceedings{Asselain2018LongtermOF,
  title={Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials},
  author={Bernard Asselain and William Barlow and John G. Bartlett and Jonas Bergh and Elizabeth Bergsten-Nordstr{\"o}m and Judith M. Bliss and Francesco M Boccardo and Clare Boddington and Jan Bogaerts and Gianni Bonadonna and Robert Bradley and Etienne G. C. Brain and Jeremy P. Braybrooke and Philippe Broet and John Bryant and Julie Ann Burrett and David A. Cameron and Mike Clarke and Alan S. Coates and Robert Randolf Coleman and R C Coombes and Candace R. Correa and Joe Costantino and Jack Cuzick and David N. Danforth and Nancy E. Davidson and Christina Davies and Lucy C Davies and Angelo di Leo and David J Dodwell and Mitchell Dowsett and F Shell Duane and Vaughan Evans and Marianne Ewertz and Bernard J Fisher and John F. Forbes and Leslie G. Ford and Jean-Claude Gazet and Richard Gelber and Lucy Gettins and Luca Gianni and Michael Gnant and Jon Godwin and Aron Goldhirsch and Pamela Goodwin and R. Gray and Daniel J. Hayes and Catherine L. Hill and James N. Ingle and Reshma Jagsi and Raimund Jakesz and Sam James and Wolfgang Janni and Hui Liu and Zulian Liu and Caroline Lohrisch and Sibylle Loibl and Liz MacKinnon and Andreas Makris and Eleftherios P Mamounas and Gurdeep S. Mannu and Miguel Mart{\'i}n and Simone Mathoulin and Louis Mauriac and P. A. Mcgale and Theresa A. McHugh and Philip W. Morris and Hiroshi Mukai and L. Norton and Yasuo Ohashi and Ivo A. Olivotto and Soon Young Paik and Hongchao Pan and Richard Peto and Martine J. Piccart and Lori J. Pierce and Philip Poortmans and Trevor J. Powles and Kathleen I Pritchard and Joseph Ragaz and Vinod Raina and Peter Ravdin and Simon Read and Meredith Regan and John George Robertson and Emiel Rutgers and Suzy M. Scholl and Dennis Slamon and Lidija Soelkner and Joseph A Sparano and Seth Steinberg and Rosemary Sutcliffe and Sandra M. Swain and Carolyn G. Taylor and Andrew Tutt and Pinuccia Valagussa and Cornelis van de Velde and Jos van der Hage and Giuseppe Viale and Gunter von Minckwitz and Yaochen Wang and Zhe Wang and Xiang Wang and Tim J Whelan and Nicholas Wilcken and Eric Winer and Norman Wolmark and Wm. Wood and Milvia Zambetti and Jo Anne Zujewski},
  booktitle={The Lancet. Oncology},
  year={2018}
}
BACKGROUND Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. METHODS We obtained information about prerandomisation… CONTINUE READING
154
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment

M Gnant, N Harbeck, C St.Thomssen
  • Breast Care 2017;
  • 2017

Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey

Krishna B. Clough, Victor Acosta-Marín, +12 authors Pascal Bonnier
  • Annals of Surgical Oncology
  • 2015